Proteasome inhibitor bortezomib targeted tumor–endothelial cell interaction in T-cell leukemia/lymphoma
✍ Scribed by Wen-Yu Shi; Li Wang; Dan Xiao; Yin Yao; Fan Yang; Xiao-Xing Jiang; Christophe Leboeuf; Anne Janin; Sai-Juan Chen; Wei-Li Zhao
- Publisher
- Springer
- Year
- 2010
- Tongue
- English
- Weight
- 420 KB
- Volume
- 90
- Category
- Article
- ISSN
- 0939-5555
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract HTLV‐I‐associated adult T‐cell leukemia/lymphoma (ATL) and human T‐cell lymphotropic virus type I (HTLV‐I)‐negative peripheral T‐cell lymphomas carry poor prognosis mainly because of acquired resistance to chemotherapy. We have shown that this disease is responsive to the combination of
## Abstract EBV‐infected cells and EBV‐associated tumors may evade CTL recognition by defective antigen processing, resulting in poor presentation of CTL epitopes. Since the proteasome is the major source of MHC class I–presented peptides, we analyzed the effect of proteasome inhibitors on the expr
## Abstract Nasal NK/T‐cell lymphoma (NL) is a rare but clinically important entity of lymphoma. Its preferential incidence in Orientals but not Caucasians suggests possible genetic predisposition. 11q deletion is common in NL, indicating certain tumor suppressor genes (TSGs) at this locus involved